Sulfonylureas as treatment choice in Diabetes Mellitus : Where are we now?

Abstract

Received: March 21, 2019; Accepted: April 01, 2019; Published: April 04, 2019 Sulfonylureas (SUs) constitute a hallmark in the treatment of Diabetes Mellitus Type 2 (DM2) and have remained the main pharmacological approach for many decades. Tolbutamide and the rest of the first-generation SUs were originated in Germany in the 1950s, while the second-generation agents such as glyburide and glipizide were released in the United States in 1984 [1]. Glimepiride, a thirdgeneration SU, became available in the United States in 1995 [2]. In 1997, SUs was the most prescribed class of oral antidiabetic agents, corresponding to over 60% of all treatment visits [3].